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Introduction: The ability to self-renew, be easily expanded in vitro and differentiate into different mesenchymal tissues,
render mesenchymal stem cells (MSCs) an attractive therapeutic method for degenerative diseases. The subsequent
discovery of their immunosuppressive ability encouraged clinical trials in graft-versus-host disease and auto-immune
diseases. Despite sharing several immunophenotypic characteristics and functional capabilities, the differences between
MSCs arising from different tissues are still unclear and the published data are conflicting.
Methods: Here, we evaluate the influence of human MSCs derived from umbilical cord matrix (UCM), bone marrow
(BM) and adipose tissue (AT), co-cultured with phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear
cells (MNC), on T, B and natural killer (NK) cell activation; T and B cells’ ability to acquire lymphoblast characteristics;
mRNA expression of interleukin-2 (IL-2), forkhead box P3 (FoxP3), T-bet and GATA binding protein 3 (GATA3), on
purified T cells, and tumor necrosis factor-alpha (TNF-α), perforin and granzyme B on purified NK cells.
Results: MSCs derived from all three tissues were able to prevent CD4+ and CD8+ T cell activation and acquisition of
lymphoblast characteristics and CD56dim NK cell activation, wherein AT-MSCs showed a stronger inhibitory effect.
Moreover, AT-MSCs blocked the T cell activation process in an earlier phase than BM- or UCM-MSCs, yielding a greater
proportion of T cells in the non-activated state. Concerning B cells and CD56bright NK cells, UCM-MSCs did not influence
either their activation kinetics or PHA-induced lymphoblast characteristics, conversely to BM- and AT-MSCs which
displayed an inhibitory effect. Besides, when co-cultured with PHA-stimulated MNC, MSCs seem to promote Treg and
Th1 polarization, estimated by the increased expression of FoxP3 and T-bet mRNA within purified activated T cells, and
to reduce TNF-α and perforin production by activated NK cells.
Conclusions: Overall, UCM-, BM- and AT-derived MSCs hamper T cell, B cell and NK cell-mediated immune response
by preventing their acquisition of lymphoblast characteristics, activation and changing the expression profile of proteins
with an important role in immune function, except UCM-MSCs showed no inhibitory effect on B cells under these
experimental conditions. Despite the similarities between the three types of MSCs evaluated, we detect important
differences that should be taken into account when choosing the MSC source for research or therapeutic purposes.* Correspondence: apaiva@histocentro.min-saude.pt
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Mesenchymal stem cells (MSCs) are multipotential non-
hematopoietic stem cells that possess the ability to self-
renew and to differentiate in response to chemical,
hormonal or structural stimuli into different lineages of
mesenchymal tissues, such as osteocytes, chondrocytes,
neurocytes and adipocytes [1-7]. MSCs can be isolated
from adult tissues, such as bone marrow, adipose tissue,
endometrial polyps, menstrual blood and so on [2], and
from fetal tissues, such as placenta, umbilical cord blood
and matrix [8,9]. Their ability to differentiate into different
tissues is variable according to their tissue of origin [4].
Bone marrow is the traditional source of human MSCs;
however, there they represent a rare population of ap-
proximately 0.001% to 0.01% of total nucleated cells
and their frequency tends to decline with increasing age
[9-12]. Although adult MSCs have the ability to expand
in culture while retaining their growth and multilineage
potential [13], compared with MSCs from fetal sources,
they undergo fewer cell divisions before they reach
senescence [4].
All MSCs seem to share a significant number of char-
acteristics, even if isolated from different sources: they are
plastic adherent, exhibit a fibroblast-like morphology,
express certain cell-surface markers (CD90, CD73 and
CD105) and are distinguished from hematopoietic precur-
sor cells and leukocytes by lacking CD34, CD45, CD14
and HLA-DR expression [3,4,14,15]. MSCs secrete several
cytokines, growth factors and extracellular matrix mole-
cules that play an important role in the regulation of
hematopoiesis, angiogenesis and in immune and inflam-
matory response [8]. Other interesting characteristics are
that MSCs can migrate and home to tissues and organs
in response to growth factors, cytokines, chemokines or
adhesion molecules and, therein, mediate immunomodu-
latory actions [10,14,16-18]. Moreover, due to their multi-
potency, MSC are a very attractive choice for clinical
applications in several immune disorders, such as arthritis,
encephalomyelitis, systemic lupus erythematosus, and in
regenerative diseases, including diabetes and skin grafting
[8,10,13,16,19]. Their low immunogenicity, immunomod-
ulatory capacity and ability to differentiate into cells that
regenerate damaged tissues, had already allowed the use
of MSCs in clinical trials for cellular and gene therapy
[10,13,14,20-22]. MSCs are able to inhibit the proliferation
and function of T, B and natural killer (NK) cells, the
cytolytic effects of antigen-primed cytotoxic T cells
(CTL) by the induction of regulatory T cells (Treg)
[14,16,20,22]. The immune modulation by MSCs seems
to be mediated by secretion of soluble factors, creating
an immunosuppressive microenvironment. This niche
also protects MSCs from environmental insults, including
cytotoxic chemotherapy and pathogenic immunity [3,23].
Beyond that, there are studies reporting that a separationof MSCs and mononuclear cells (MNC) by a semi-per-
meable membrane does not abrogate the inhibition of
lymphocyte proliferation [20,24-28].
Different studies affirm that different molecules expressed
by MSCs are responsible for, or could contribute to,
suppression of lymphocyte proliferation [10,14,20,29-31].
MSCs have also been demonstrated to interfere with
dendritic cells (DC) differentiation, maturation and func-
tion, by soluble factors. Consequently, this interference can
be involved in suppression of T cells proliferation, as well
as in the induction of regulatory antigen-presenting cells
[10,18,20,30,32,33]. Moreover, MSCs seem to differently
modulate the function of the various T cell subsets, which
is explained in detail in the review of Duffy et al. [34].
In this study, we performed co-cultures of phytohem-
agglutinin (PHA)-stimulated MNC with MSCs from dif-
ferent sources (umbilical cord matrix, adipose tissue and
bone marrow), for four days, to evaluate the immunomod-
ulatory effects of MSCs on the acquisition of lymphoblast
characteristics, by T and B lymphocytes, and on immune
cell activation, which has been assessed by the expression
of CD69, CD25 and HLA-DR on CD4+ and CD8+ T cells,
B cells and NK cells. After cell sorting of the different
compartments of activated T cells, we have measured
transcripts for T-bet, GATA3 and FoxP3, to infer about T
cell polarization to Th1, Th2 or Treg, respectively; the
expression of mRNA for IL-2 was also quantified. In
addition, the different compartments of activated NK cells
were purified and mRNA expression of TNF-α, perforin
and granzyme B was measured to evaluate the effect of
MSCs on these proteins with an important role in NK cell
function.
This study shows that MSCs derived from different
tissues possess different immunosuppression capabilities
and their action varies with the immune cell type.
Methods
MSCs isolation, purification and co-culture with peripheral
blood mononuclear cells
Co-cultures were carried out in six-well tissue culture
plates (Falcon, Becton Dickinson Biosciences, BD, San Jose,
CA, USA) with peripheral blood mononuclear cells (MNC)
from healthy donors and allogeneic human MSCs from the
three different sources, bone marrow (BM), adipose tissue
(AT) and umbilical cord matrix (UCM, also known as
Wharton’s jelly MSCs), in the presence or absence of
phytohemagglutinin (PHA, Irvine Scientific, Santa Ana,
CA, USA), as mitogenic stimulus. Biological samples
were obtained from healthy donors, with informed consent,
and the study was approved by the Ethics Committees of
Instituto Português de Oncologia de Lisboa Francisco
Gentil (Laws nº 97/95, nº 46/2004) and Maternidade de
Bissaya Barreto (ref. 356/Sec). MSCs were isolated from at
least two different healthy donors for each cell source and
Ribeiro et al. Stem Cell Research & Therapy 2013, 4:125 Page 3 of 16
http://stemcellres.com/content/4/5/125appropriately cultured and purified to homogeneity, as
previously described [35-37].
In short, MNC from BM aspirates were plated at a
density of 2 × 105 cells/cm2 on T-175 flasks (Falcon BD)
in Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% fetal bovine serum, streptomycin
(0.025 μg/ml), penicillin (0.025 U/ml) (Gibco, Life Tech-
nologies, Paisley, UK), at 37°C and 5% CO2 in a humidi-
fied atmosphere. Medium was changed twice a week.
BM-MSCs were isolated based on adherence to plastic,
and near cell confluence (70 to 80%) exhausted medium
was removed from the flasks, cells were washed with
phosphate buffered saline (PBS, Gibco) and detached
from the flask by adding Accutase solution (Sigma, St.
Louis, MO, USA) for seven minutes at 37°C. Isolated
BM-MSCs expressed their characteristic immunophe-
notype being CD73, CD90 and CD105 positive and
negative for CD31, CD34, CD45 and CD80. Cell number
and viability were also determined using the Trypan
Blue (Gibco) exclusion method [36].
For AT-MSCs isolation, AT samples were collected into a
conical tube containing PBS supplemented with 20 mg/mL
of human serum albumin, washed extensively with PBS
and then digested with a 0.1% (w/v) Collagenase Type II
(Sigma) solution for 30 minutes at 37°C. After neutralizing
the enzymatic activity of Collagenase with DMEM 10%
fetal bovine serum, 1% (v/v) penicillin (10,000 U/mL)/
streptomycin (10,000 g/mL) (Gibco) and 0.1% (v/v) Fungi-
zone (Gibco), the adipose tissue was centrifuged at
2,500 rpm for 10 minutes, in order to obtain a high dens-
ity stromal vascular fraction. The contaminating red blood
cells were lysed by resuspending the pellet in 160 mM
NH4Cl solution for 10 minutes at room temperature.
Once again, the reaction was stopped with DMEM 10%
fetal bovine serum, followed by centrifugation. Then, the
suspension was filtered through a nylon mesh of 100 μm
to eliminate the cellular debris and a cell count was
performed. After plating and incubating overnight at
37°C, 5% CO2, the cells were washed with PBS in order to
remove non-adherent cells. The cells were maintained at
37°C, 5% CO2, in a fully humidified atmosphere in DMEM
10% fetal bovine serum and the medium changed every
three to four days. When cells reached near 80% conflu-
ence, cells were harvested using Accutase and plated into
new T-flasks (3,000 cells/cm2). The number of cells and
cellular viability were also determined [37].
For UCM-MSCs’ isolation, umbilical cords were rinsed
with PBS (Gibco), arteries and veins were dissected and
the remaining tissue fragments were digested with 0.1%
collagenase type II (Sigma) for four hours at 37°C. The
solution was filtered and washed with Iscove’s Modified
Dulbecco’s Media (IMDM, Gibco) supplemented with
streptomycin (0.025 μg/mL) and penicillin (0.025 U/mL)
(Gibco). The cell number was determined using theTrypan Blue (Gibco) exclusion method. Cells were plated
in T-flasks at an initial density of 10,000 cells/cm2 using
DMEM supplemented with 10% fetal bovine serum, Stem-
PRO® MSC Serum-Free Medium, or StemPRO® MSC SFM
XenoFree (all from Gibco) culture media and kept at 37°C
and 5% CO2 in a humidified atmosphere. When using
StemPRO® MSC SFM/StemPRO® MSC SFM XenoFree
cell culture, surfaces were pre-coated with CELLstartTM
CTSTM (Invitrogen, Life Technologies, Paisley, UK)
following the manufacturer’s instructions. After 48 hours
of culture, the nonadherent cells were removed and cells
were maintained by renewing the medium every three
to four days. Cultures were monitored by microscopy
(Olympus CK40 optical microscope, Central Valley, PA,
USA) in order to assess cell morphology and spreading [35].
All assays were performed using MSCs between pas-
sage 3 and 5 and, prior to cell cultures, MSCs’ identity
was confirmed by immunophenotypic analysis: 5 × 105
cells were harvested to perform flow cytometry analysis
for the MSCs’ markers CD105, CD73 and CD90. MNC
were purified from heparinized peripheral blood by density-
gradient centrifugation (Lymphoprep, Axis-Shield PoC AS,
Oslo, Norway) at 1,310 × g, for 20 minutes. Cell cultures
were maintained in RPMI 1640 with GlutaMax medium
(Invitrogen) supplemented with 10% fetal bovine serum
(Gibco) and antibiotic-antimycotic (Gibco). Control cul-
tures consisted of MNC in the absence of MSCs, with or
without PHA stimulation (17 replicates for each condi-
tion). With this strategy, different sets of co-cultures were
generated: MNC+ BM-MSCs and MNC+PHA+BM-
MSCs (five replicates for each condition); MNC+UCM-
MSCs and MNC+PHA +UCM-MSCs (seven replicates
for each condition); MNC+AT-MSCs and MNC+PHA +
AT-MSCs (five replicates for each condition). A total
of 300,000 MNC were added to each well and, in the
conditions where the cells were activated by PHA, a
concentration of 10 μg/mL of the mitogen was used; in
each well where MSCs were included, we added 30,000
cells, establishing a ratio of 10:1 (MNC:MSC). These
plates were kept in culture for four days at 37°C, in 5%
CO2 and 90% humidity. After four days under each condi-
tion, the cultured cells were washed with PBS 1X, pH7.4
(Gibco) and centrifuged at 540 × g for five minutes.
Identification and quantification of the different
compartments of activated T, B and NK cells
Immunofluorescent staining
Each cell culture was used for two purposes: (1) pheno-
typic study by flow cytometry, to evaluate the acquisition
of lymphoblast characteristics by T and B cells and the
activation kinetic of lymphocytes and (2) cell sorting and
purification of the compartments of activation of lym-
phocytes, for gene expression analysis on T and NK cells.
In order to identify different lymphocyte subtypes, we
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following fluorochromes: fluorescein isothiocyanate (FITC),
phycoerythrin (PE), peridinin chlorophyll protein (PerCP),
phycoerythrin cyanin 7 (PE-Cy7 or PC7), allophycocyanin
(APC), allophycocyanin hillite 7 (APC-H7), pacific blue
(PB) and amcyan (AC). T cells were identified by CD3 PB
(clone UCHT1, BD Pharmingen, San Diego, CA, USA)
expression and, among this cell population, CD4+ T and
CD8+ T cells were identified based on CD4 FITC (clone
13B8.2, Beckman Coulter, Brea, CA, USA) and CD8 AC
(clone SK1, BD) expression, respectively; CD19 FITC
(clone SJ25C1, BD) or CD19 PC7 (clone J4.119, Beckman
Coulter) were used to identify B cells, and CD56 PC7
(clone N901, Beckman Coulter) positivity, in the absence
of CD3 expression, for NK cells; finally, we used CD90
APC (clone 5E10, BD Pharmingen) to identify and exclude
MSCs. To define the different stages of lymphocyte activa-
tion, we used mAb against CD69 PE (clone TP1.56.3,
Beckman Coulter), CD25 APC-H7 (clone M-A251, BD
Pharmingen) and HLA-DR PerCP (clone G46-6, BD
Pharmingen).
Flow cytometry data acquisition and analysis
Cells were acquired on a FACS Canto™ II (BD) using
FACSDiva software (BD), and 100,000 events were ana-
lyzed using Infinicyt 1.5 software (Cytognos, Salamanca,
Spain). Through multi-parametric flow cytometry analysis,
we identified four different subpopulations of CD4+ and
CD8+ T cells: non-activated CD69-CD25-HLA-DR-; earlier
activated CD69+CD25-HLA-DR-; intermediate activated
CD69+CD25+HLA-DR-; and later activated CD69+CD25+
HLA-DR+. In B cells, CD56dim NK and CD56bright NK
cells, only three subpopulations were quantified: non-
activated CD69-CD25-, earlier activated CD69+CD25- and
activated CD69+CD25+.
Cell sorting of the activation compartments of
T and NK cells
Cultured lymphocytes were purified by fluorescence-acti-
vated cell sorting, using FACSAria™ flow cytometer (BD).
Each compartment of activated lymphocytes were sorted
according to their typical phenotype: CD69-CD25-HLA-
DR-, CD69+CD25-HLA-DR-, CD69+CD25+HLA-DR- and
CD69+CD25+HLA-DR+ for T cells; and CD69-CD25-,
CD69+CD25- and CD69+CD25+ for NK cells.
Gene expression analysis
The cell sorted subsets were centrifuged for five minutes
at 300 × g and the pellet resuspended in 350 μL of RLT
Lysis Buffer (Qiagen, Hilden, Germany) and total RNA
extraction performed with the RNeasy Mini kit (Qiagen)
according to the supplier’s instructions. Total RNA was
eluted in a 50 μl volume of RNase-free water. In order
to quantify the amount of total RNA extracted and toverify RNA integrity, samples were analyzed using a 6000
Nano Chip kit, in an Agilent 2100 bioanalyzer (Agilent
Technologies, Walbronn, Germany) and 2100 expert soft-
ware, according to the manufacturer’s instructions. RNA
was reverse transcribed with SuperScript III First-Strand
Synthesis SuperMix for qRT-PCR (Invitrogen), according
to the manufacturer’s instructions. Relative quantification
of gene expression by real-time PCR was performed in
the LightCycler 480 II (Roche Diagnostics, Rotkreuz,
Switzerland). Real-time PCR reactions were carried
out using 1 X QuantiTect SYBR Green PCR Master Mix
(Qiagen), 1 X QuantiTect Primer Assay (TNF-α: QT01079561;
FoxP3: QT00048286; IL2: QT00015435; Tbet: QT00042217;
Gata3: QT00095501; Granzime B: QT01001875; Perforin:
QT00199955) (Qiagen) and 20 ng of cDNA sample, in a
total volume of 10 μl. The reactions were performed using
the following thermal profile: 15 minutes at 95°C, and
40 cycles of 15 sec at 94°C, 30 sec at 55°C and 30 sec at
72°C. All samples were run in duplicate. Melting point
analysis was done to ensure the amplification of the
specific product. Real-time PCR results were analyzed
with the LightCycler software (Roche Diagnostics).
GeNorm Reference Gene Selection kit (PrimerDesign
Ltd., Southampton, England) in conjunction with the
geNorm software (PrimerDesign Ltd.) were used to select
the reference genes to normalize data. The reference genes
used for gene expression analysis, in T cells, were the spli-
cing factor 3a, subunit 1 (SF3A1) and the topoisomerase
(DNA) I (TOP1) and, in NK cells, were the ubiquitin C
(UBC) and the 18S rRNA. The normalized expression
levels of the genes of interest were calculated by using the
delta-Ct method.
Statistical analysis
To determine the statistical significance of the differences
observed between different culture conditions, non-para-
metric Mann–Whitney test and Wilcoxon paired-sample
test were performed, using Statistical Package for Social
Sciences (IBM SPSS, version 17.0, Armonk, NY, USA).
Data were expressed as mean percentage ± standard devi-
ation. Statistically significance differences were considered
when P-value was lower than 0.05.
Results
MSCs prevent T and B cells’ acquisition of lymphoblast
characteristics, except for UCM-MSCs that are unable to
inhibit this process in B and CD56bright NK cells
Lymphocytes undergo multiple rounds of clonal division
after mitogenic stimulation. Consequently, in the presence
of PHA, lymphocytes start to proliferate and the cells
acquire a lymphoblast morphology, which can be observed
by flow cytometry as an increased forward scatter (FSC,
corresponding to an increase in cell size) and side scatter
(SSC, corresponding to an increased granularity) light
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of FSC-Area vs FSC-Height dot plot allowed an easy
identification and exclusion of doublets.
MNC were co-cultured with BM-, UCM- and AT-MSCs
at the ratio of 10:1, in the presence of PHA. When com-
pared with the MNC+ PHA control assay, in the presence
of MSCs, the frequency of CD4+ and CD8+ T cells with
increased FSC and SSC properties was lower, as shown in
Table 1 (P <0,05 for BM-, UCM- and AT-MSC). Although
only 18% of B cells acquired lymphoblast characteristics
in control assay, a marked and statistically significant
decrease of the percentage of B cells with increased FSC
and SSC properties occurred in the presence of BM- and
AT-MSCs, whereas UCM-MSCs did not influence this
process on B cells under these experimental conditions.MSCs derived from different tissues influence
differentially the distribution of T, B and NK lymphocytes
among non-activated and activated compartments
To investigate the kinetics of lymphocyte activation, in
the presence or absence of PHA and MSCs arisen from
different tissues, we analyzed four subpopulations of
both CD4+ and CD8+ T cells, phenotypically defined as:
CD69-CD25-HLA-DR- (non-activated), CD69+CD25-HLA-
DR- (earlier activated), CD69+CD25+HLA-DR- (intermedi-
ate activated) and CD69+CD25+HLA-DR+ (later activated),
in different culture conditions. Likewise, we identified three
subpopulations of B cells, CD56dim and CD56bright NK
cells: CD69-CD25- (non-activated), CD69+CD25- (earlier
activated) and CD69+CD25+ (activated).
As expected, lymphocytes from MNC cultures undergo
activation only after exposure to PHA (Table 2). In these
culture conditions, we observe that the co-culture ofFigure 1 Cells displaying increased forward scatter and side scatter li
Bivariate dot plot histogram illustrating mononuclear cell (MNC) culture aft
populations: A) MNC with low forward scatter (FSC) and side scatter (SSC)
properties. Right: Density histogram illustrating the DNA content of MNC fr
staining, and proving that cells with increased FSC and SSC are actively proMSCs from different sources presents a different effect in
the inhibition of the activation.
Analyzing CD4+ and CD8+ T cells from MNC culture,
in the presence of PHA and absence of MSCs, after four
days of culture, we observe that the largest proportion of
cells displays an intermediate activated phenotype (Table 2);
the presence of either BM- or UCM-MSCs in the cell
culture increases the frequency of earlier activated cells
(P <0.05 for both MSCs types and for both T cell sub-
populations); whereas the presence of AT-MSCs is
associated with a significant increase of cells within the
non-activated compartment (P <0.05) and, to a lesser
extent, in earlier activated compartment (P <0.05) and,
consequently, is observed an important decrease in inter-
mediate activated compartment (P <0.05), for both CD4+
and CD8+ T cells (Table 2).
Concerning B cells, when stimulated with PHA in the
absence of MSCs, the earlier activated compartment is
the most representative. As a consequence of BM and
AT-MSCs, B cells are partially inhibited to proceed to
the earlier activated stage; as a result, the frequency of
cells in that compartment is diminished, and this decrease
has statistical significance for both MSCs types (Table 2).
Conversely, UCM-MSCs seem to be unable to inhibit the
development of B cell activated phenotype (Table 2).
Finally, co-cultures of MSCs with MNC in the presence
of PHA, present similar results for CD56dim NK cells, re-
gardless of the MSC nature and consist of an augmentation
of the non-activated compartment (P <0.05 for all MSCs,
compared with MNC+PHA), at the expense of the earlier
activated compartment (Table 2). However, a distinct
behavior is observed in CD56bright NK cells, in which the
presence of PHA has a significantly smaller effect, com-
pared to the other lymphocyte populations consideredght dispersion properties correspond to proliferating cells. Left:
er phytohemagglutinin (PHA) stimulation, displaying two distinct cell
light dispersion properties and B) MNC with increased FSC and SSC
om population A (green) and B (red), measured after propidium iodide
liferating.
Table 1 Percentage of cells displaying increased forward scatter and side scatter light dispersion properties
% of cells with
increased FSC and SSC
MNC + PHA MNC + PHA + BM-MSCs MNC + PHA + UCM-MSCs MNC + PHA + AT-MSCs
n = 17 n = 5 n = 7 n = 5
Total mononuclear cells 51 ± 3 31 ± 4a; d 41 ± 15d 21 ± 10a; c; d
Total T cells 56 ± 2 31 ± 6a; d 47 ± 19d 19 ± 13a; c; d
CD4+ T cells 54 ± 4 26 ± 3a; d 47 ± 22d 15 ± 11a; c; d
CD8+ T cells 59 ± 4 38 ± 11a; d 49 ± 16d 21 ± 7a; b; c; d
B cells 18 ± 3 9 ± 1a 18 ± 9b 7 ± 4a; c; d
Percentage (mean ± standard deviation) of cells with increased forward scatter and side scatter light dispersion characteristics after PHA stimulation, in the
absence or in the presence of MSCs from different sources, within the total MNC in culture and within the following cell populations: total T cells, CD4+ T cells,
CD8+ T cells and B cells.
Results are expressed as mean percentage ± standard deviation. Statistically significant differences were considered when P <0,05 for Mann–Whitney test:
acomparing with MNC + PHA; bcomparing with MNC + PHA + BM-MSCs; ccomparing with MNC + PHA + UCM-MSCs. Statistically significant differences were
considered when P <0,05 for Wilcoxon paired-sample test: dcomparing with MNC + PHA.
AT, adipose tissue; BM, bone marrow; MNC, mononuclear cells; MSCs, mesenchymal stem cells PHA, phytohemagglutinin; UCM, umbilical cord matrix.
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observe a decreased percentage of CD56bright NK cells
undergoing activation, when co-cultured with BM- or
AT-MSCs (P <0.05 for both); conversely, UCM-MSCs
have no effect on the kinetics of CD56bright NK cells’ acti-
vation (Table 2).
MSCs differentially influence mRNA expression of FoxP3,
T-bet, Gata3 and IL-2 on T cells
The analysis of gene expression levels of transcription
factors and IL-2, among the different T cell activation
compartments, previously sorted and purified, was per-
formed in order to better understand the immunomod-
ulatory mechanisms underlying MSCs.
In a control assay (MNC + PHA), FoxP3 mRNA levels
increase along with the progress of T cell activation;
notably, the presence of AT-MSCs strongly increases
FoxP3 transcripts (P <0.05; Figure 2A). Attending to T-bet,
whose mRNA expression increases in the earlier activated
stage of the control assay, an increase that is not main-
tained in intermediate and later activation stages, it is
observed that MSCs further increase and maintain their
expression along the activation process (P <0.05; Figure 2B).
Conversely, GATA3 mRNA is not induced by PHA stimu-
lation and the presence of MSCs do not increase GATA3
mRNA levels (Figure 2C). Finally, in control assays, the
maximal expression of IL-2 mRNA is observed in an
earlier activated stage, wherein the presence of MSCs of
any source under study leads to a reduction, which is
more notable for AT-MSCs (P <0.05 for BM- and AT-
MSCs), as depicted in Figure 2D.
MSCs differentially influence mRNA expression of
perforin, granzyme B and TNF-α on NK cells
Our data show that, on earlier activated and activated
NK cells, both TNF-α and perforin mRNA expression is
suppressed by all of the three types of MSCs tested(Figure 3A, B, respectively). Concerning granzyme B mRNA
expression, we observed that UCM-MSCs induce an in-
creased expression of this cytotoxic protein on activated
NK cells, whereas BM- and AT-MSCs slightly reduce it
(Figure 3C).
Discussion
To assess the influence of MSCs from different sources
in the induction of lymphoblast characteristics on T and
B cells, ability of T, B and NK cells to progress along the
activation process and mRNA expression of genes related
to T cell polarization and NK cytotoxic activity, MNC
cultures, in the absence/presence of PHA and in the
absence/presence of MSCs, were carried out.
PHA is a lectin with the ability to bind and crosslink
different cell membrane glycoproteins, leading to the poly-
clonal activation of lymphocytes [38]. Although TCR, CD3
and CD2 crosslinking by PHA mimics the T cells’ first sig-
nal of activation, leading to PKC activation and increasing
the cytoplasmatic calcium levels, it is not sufficient to pro-
mote T cell activation, being required accessory signals
given by antigen-presenting cells, which are also essential
for IL-2 expression by T cells and, consequently, for their
proliferation [38-41]. The early activation marker CD69 is
expressed on NK, B and T cell surface 4 hours after activa-
tion and is implicated on the transcription of IL-2 and
TNF-α; 12 to 24 hours after cell activation, the α subunit
of IL-2 receptor (CD25) expression is up-regulated, allow-
ing the assembling of the high-affinity IL-2 receptor on T
cell plasmatic membrane; finally, between 48 to 60 hours,
T cells initiate HLA-DR expression [42-45].
According to our data, both BM- and AT-MSCs, when
co-cultured with PHA-stimulated MNC, inhibit B cell
acquisition of lymphoblast characteristics and progression
from non-activated to earlier activated stage, wherein
AT-MSCs display the strongest inhibitory capability, which
corroborates with the results published by Bochev et al.















Cell type Subpopulation n = 17 n = 5 n = 7 n = 5 n = 17 n = 5 n = 7 n = 5
Total T cells 82 ± 5 80 ± 11 80 ± 7 86 ± 5 86 ± 3 79 ± 8 71 ± 17 86 ± 5
CD4+ T cells 81 ± 5 81 ± 9 77 ± 9 84 ± 3 77 ± 3 84 ± 7 67 ± 8 76 ± 10
CD69-CD25-HLA-DR- 100 ± 0 100 ± 0 99 ± 2 100 ± 0 25 ± 7 23 ± 8 18 ± 9 43 ± 17a; b; c; d
CD69+CD25-HLA-DR- 0 ± 0 0 ± 0 1 ± 2 0 ± 0 6 ± 1 14 ± 4a; d 15 ± 8a; d 13 ± 1a; d
CD69+CD25+HLA-DR- 0 ± 0 0 ± 0 0 ± 0 0 ± 0 67 ± 7 58 ± 6a 66 ± 17 43 ± 18a; d
CD69+CD25+HLA-DR+ 0 ± 0 0 ± 0 0 ± 0 0 ± 0 3 ± 2 4 ± 2 2 ± 2 1 ± 0
CD8+ T cells 19 ± 5 19 ± 9 23 ± 9 14 ± 3 23 ± 3 16 ± 7 33 ± 8 24 ± 10
CD69-CD25-HLA-DR- 99 ± 0 99 ± 2 98 ± 3 100 ± 1 18 ± 10 22 ± 3 12 ± 1b 41 ± 12a; b; c; d
CD69+CD25-HLA-DR- 1 ± 0 1 ± 2 2 ± 2 0 ± 1 9 ± 1 16 ± 4a; d 18 ± 9a; d 14 ± 2a
CD69+CD25+HLA-DR- 0 ± 0 0 ± 0 0 ± 0 0 ± 0 68 ± 11 59 ± 6a 67 ± 10 45 ± 14a; b; c; d
CD69+CD25+HLA-DR+ 0 ± 0 0 ± 0 0 ± 0 0 ± 0 4 ± 2 2 ± 3d 2 ± 2 1 ± 1
B cell 2 ± 0 2 ± 1 4 ± 4 3 ± 2 3 ± 1 4 ± 1 4 ± 3 3 ± 2
CD69-CD25- 98 ± 1 95 ± 4 97 ± 3 98 ± 1 40 ± 6 63 ± 23 37 ± 9 72 ± 15a; d
CD69+CD25- 2 ± 1 5 ± 4 3 ± 3 2 ± 1 56 ± 7 32 ± 15d 60 ± 6b 27 ± 14a; d
CD69+CD25+ 0 ± 0 0 ± 0 0 ± 0 0 ± 0 4 ± 3 5 ± 10 4 ± 4 1 ± 1
Total NK cells 16 ± 5 19 ± 10 16 ± 5 12 ± 5 12 ± 2 20 ± 9 20 ± 9 11 ± 5
CD56bright
NK cells
3 ± 1 2 ± 1 3 ± 2 4 ± 3 8 ± 0 6 ± 3 6 ± 5 8 ± 4
CD69-CD25- 99 ± 0 99 ± 1 99 ± 3 100 ± 1 82 ± 2 94 ± 2a; d 80 ± 20 97 ± 1a; b; d
CD69+CD25- 1 ± 0 1 ± 1 1 ± 3 0 ± 1 17 ± 2 6 ± 2a; d 18 ± 17 3 ± 1a; b; d
CD69+CD25+ 0 ± 0 0 ± 0 0 ± 0 0 ± 0 1 ± 0 1 ± 0 2 ± 3 1 ± 0
CD56dim NK cells 97 ± 1 98 ± 1 97 ± 2 96 ± 3 92 ± 0 94 ± 3 94 ± 3 92 ± 4
CD69-CD25- 97 ± 2 96 ± 7 97 ± 4 99 ± 1 29 ± 3 73 ± 18a; d 74 ± 6a; d 79 ± 19a; d
CD69+CD25- 3 ± 2 4 ± 7 3 ± 4 1 ± 1 68 ± 2 25 ± 17a; d 25 ± 6a; d 20 ± 19a; d
CD69+CD25+ 0 ± 0 0 ± 0 0 ± 0 0 ± 0 3 ± 0 1 ± 1 1 ± 1 1 ± 0
Distribution (mean ± standard deviation) of total T cells, CD4+ and CD8+ T cells, B cells, total NK cells and CD56dim and CD56bright NK cells in the MNC culture and
among the following activation stages: non-activated CD69-CD25-HLA-DR-, earlier activated CD69+CD25-HLA-DR-, intermediate activated CD69+CD25+HLA-DR-, and
later activated CD69+CD25+HLA-DR+, for T cell subpopulations; and non-activated CD69-CD25-, earlier activated CD69+CD25- and activated CD69+CD25+, for B cells
and NK cell subpopulations. MNC were subjected to different culture conditions: absence or presence of PHA and absence or presence of MSCs from
different sources.
Results are expressed as mean percentage ± standard deviation. Statistically significant differences were considered when P <0,05 for Mann–Whitney test:
acomparing with MNC + PHA; bcomparing with MNC + PHA + BM-MSCs; ccomparing with MNC + PHA + UCM-MSCs. Statistically significant differences were
considered when P <0,05 for Wilcoxon paired-sample test: dcomparing with MNC + PHA.
AT, adipose tissue; BM, bone marrow; MNC, mononuclear cells; MSCs, mesenchymal stem cells; PHA, phytohemagglutinin; UCM, umbilical cord matrix.
Ribeiro et al. Stem Cell Research & Therapy 2013, 4:125 Page 7 of 16
http://stemcellres.com/content/4/5/125[46], who showed that AT-MSCs had a stronger ability to
inhibit immunoglobulin (Ig) production by B cells than
BM-MSCs. Conversely, UCM-MSCs do not influence either
B cells’ ability to acquire lymphoblast characteristics or
the distribution among the activation compartments.
Several studies describe the inhibitory effect of MSCs
on B cell proliferation, activation, ability to differentiate to
plasma cells and/or produce Ig [28,46-50], demonstrating
that human BM-MSCs block stimulated B lymphocytes
on G0/G1 phases of the cell cycle and interfere with the
phosphorylation status of ERK1/2 and p38 MAPK [50].
Conversely to T cells, where a number of studies have
been done to unveil the mechanisms beneath MSCs’suppression of the immune response, there are few studies
concerning this matter on B cells. Based on the results
yielded by previous studies on T cells, it is hypothesized
that programmed cell death 1 ligand 1 (PD-L1), alterna-
tively cleaved CCL2, prostaglandin E2 (PGE2), transform-
ing growth factor-β (TGF-β), indoleamine 2,3-dioxygenase
(IDO) and hepatocyte growth factor (HGF), whose consti-
tutive or induced expression on MSCs had already been
demonstrated, might be the effector molecules supporting
B cell inhibition. On mouse and murine models, PD-L1
[28,51,52] and alternatively cleaved CCL2 [52,53] were
demonstrated to mediate MSCs inhibition of B cells; in
contrast, TGF-β and IDO were not involved in this
Figure 2 mRNA expression of FoxP3, Tbet, GATA3 and IL-2 among the different T cells’ activation compartments. Semi-quantitative
analysis of FoxP3 (A), Tbet (B) GATA3 (C), and IL-2 (D) mRNA expression for each activation stage phenotypically identified on T cells: non-activated
(CD69-CD25-HLA-DR-), earlier activated (CD69+CD25-HLA-DR-), intermediate activated (CD69+CD25+HLA-DR-) and later activated (CD69+CD25+HLA-DR+).
* Differences statistically significant (P <0.05, Mann–Whitney and Wilcoxon paired-sample test). AT, adipose tissue; BM, bone marrow; MNC, mononuclear
cells; MSCs, mesenchymal stem cells; PHA, phytohemagglutinin; UCM, umbilical cord matrix.
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human B cell function [54,55], but its relevance on
MSC-induced B cell inhibition is still unknown.
In our experimental design, MSCs can act directly on
B cells, but it should also be taken into account theirsuppressive effect on the other MNC in culture which,
in turn, will condition B cell activation and proliferation.
Indeed, by preventing T cell activation, cytokine production
and down-regulating BAFF expression on DC [56], MSCs
can indirectly and efficiently hamper B cell activation,
Figure 3 mRNA expression of perforin, granzyme B and TNF-α among the different NK cells’ activation compartments. Semi-quantitative
analysis of TNF-α (A), perforin (B) and granzyme B (C) gene expression for each cell activation stage phenotypically identified on NK cells:
non-activated (CD69-CD25-), earlier activated (CD69+CD25-) and activated (CD69+CD25+). * Differences statistically significant (P <0.05, Mann–Whitney and
Wilcoxon paired-sample test). AT, adipose tissue; BM, bone marrow; MNC, mononuclear cells; MSCs, mesenchymal stem cells; PHA, phytohemagglutinin;
UCM, umbilical cord matrix.
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evidence that the microenvironment conditions, such as
the type of stimulus, presence of other cell types and
MSC:B cell ratio are determinant for the effect of MSC
on B cells [48,50,51,57-59]. In fact, under appropriate
conditions, MSCs can enhance B cell proliferation, dif-
ferentiation and Ig production [50,52,58,60].Here we describe, for the first time, that the origin of
MSCs is essential in determining B cell fate, demon-
strating that AT- and BM-MSCs inhibit B cell activation
and acquisition of lymphoblast characteristics, whereas
UCM-MSCs do not, under the same culture conditions.
All the three types of MSCs tested, when co-cultured
with MNC in the presence of PHA, inhibit the acquisition
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lymphocytes, more marked for AT-MSCs, followed by
BM-MSCs and, finally, UCM-MSCs. Similarly, all MSCs
from different tissues displayed the ability to suppress
the activation of CD4+ and CD8+ T cells. Remarkably,
whereas UCM- and BM-MSCs block the cell activation
after the up-regulation of CD69 (at the earlier activated
stage), AT-MSCs strongly inhibit the passage from non-
activated to earlier activated stage, yielding a great propor-
tion of non-activated T cells after mitogenic stimulus.
Again, the effect of UCM-MSCs is milder, as the percentage
of cells achieving the intermediate activated stage does not
differ from that observed in the absence of MSCs. Likewise,
the three types of MSCs inhibit IL-2 mRNA expression on
T cells, more evident in earlier-activated stage, in which
UCM-MSCs display a more moderate effect. In summary,
MSCs suppress T cell immune response by reducing their
proliferation and blocking their activation, what is in part
a consequence of IL-2 reduction, a cytokine essential for
T cell proliferation and differentiation, being described
that the addition of exogenous IL-2 partially reverts MSC-
mediated inhibition [61].
MSCs’ ability to inhibit T cell proliferation, activation
and IL-2 expression is extensively described in the literature
[59,62-68], as well as the capability to modulate the expres-
sion of other cytokines and diminish CTL cytolytic func-
tion. These capabilities are, at least in part, mediated by
soluble factors produced by MSCs [63,69], namely TGF-β
[70], PGE2 [59,71-73], IDO [59,74,75], leukemia inhibitory
factor (LIF) [76], HLA-G5 [59,77-79], galectin [77,80-83],
Jagged-1 [84], adenosine [85,86] and semaphorin-3A
[80,87], and/or cellular contact and interaction between
the MSCs’ surface proteins HLA-G1 [78,88], PD-L1 [28],
CD200 [89,90] and B7-H4 [91-93], and the respective
receptors on T cells.
T cell proliferation is inhibited by LIF [76], TGF-β
[70], Jagged-1 [84], PGE2 [59,71-73], IDO [59,74,75],
galectin-1 and −3 [80-83], HLA-G5 and HLA-G1
[59,77-79], PD-L1 [28], B7-H4 [91-93], semaphorin-3A
[63,80,84,87] and adenosine [85]. Both semaphorin-3A
and adenosine prevent T cell proliferation by antagonizing
signaling pathways downstream of TCR and CD28; adeno-
sine is also involved in the inhibition of IL-2, CD25, IFN-γ
and TNFα expression and decreases cytolytic ability of
CTL [85-87]. The negative co-stimulatory molecule B7-
H4 prevents T cell activation, proliferation and production
of IL-2 and other cytokines, by inhibiting NF-kB, ERK1/2
and JNK; B7-H4 also down-regulates CD69 and CD25
expression on T cells [91-93].
Besides the effect exerted directly on T cells, indirect
suppression also occurs by inhibition of DC maturation, as
demonstrated for BM-MSCs, consisting of the reduction of
endocytosis and antigen processing capability, decreased ex-
pression of co-stimulatory molecules, chemokine receptorsand cytokines essential for T cell activation (such as IL-12)
and, consequently, diminishing DC’s capability to prime T
cells, whereas stimulating IL-10 expression and, therefore,
inducing tolerogenic DC’s ability to expand CD4+ Treg
[52,57,63,72,94,95].
As previously described by our group [96] and others
[97], MNC stimulation with PHA induces the expression
of IFN-γ and IL-2, which activate antigen-presenting cells,
contributing to the increased expression of IL-1, -6, -12
and TNF-α described on PHA-stimulated MNC [97-99],
and creating the conditions for Th1 polarization (IFN-γ
plus IL-12), characterized by T-bet expression. In fact, we
observe an increased T-bet mRNA expression in all the
three T cell activation compartments sorted and purified
from MNC stimulated with PHA and the presence of
MSCs seems to potentiate and preserve T-bet expression
along the activation stages. When FoxP3 mRNA expres-
sion is concerned, we observe an augmentation in inter-
mediate and later activated T cells from PHA-stimulated
MNC cultures, more pronounced in the presence of MSCs,
especially AT-MSCs. Thus, our data show that, using
this experimental design, MSCs favor T cell differentiation
toward Th1 and Treg, but we have to be aware that this
effect is exerted on a small number of cells, since, in the
presence of MSCs, the percentage of T cells undergoing
activation is very limited.
In opposition to the results obtained for T-bet mRNA
expression, MSCs support to Treg (CD4+FoxP3+) induc-
tion and expansion is widely described in the literature,
contributing for this occurrence PGE2, TGF-β, HLA-G5,
IDO, LIF, IL-10 and CD200, whose expression in-
creases after MSCs exposure to pro-inflammatory fac-
tors [34,57,59,63,70,75,76,79,89,100-106].
Although the increased T-bet expression on T cells may
apparently be contradictory to previous works affirming
that MSCs inhibit Th1 polarization [34,100,107-109], it is
worth mentioning that, in the present work, T-bet mRNA
expression was measured within each one of the four
purified T cells’ activation compartments, while in the
aforementioned studies the sense of T cell polarization
was inferred by the pattern of cytokines expressed, specif-
ically by the decreased IFN-γ levels. As our data clearly
demonstrate, the presence of MSCs reduce the number of
T cells undergoing activation, which conditions an overall
reduction of IFN-γ levels on the culture supernatant, even
assuming the polarization is skewed toward Th1. In fact, it
has not already been described as a direct mechanism by
which MSCs inhibit Th1 polarization, being hypothesized
that it is an indirect effect of both the impairment of DC
capability to prime naive T cells and the induction of Treg
expansion [34]. Furthermore, MSCs decrease IFN-γ ex-
pression in human mixed lymphocyte reaction [63], human
MNC cultures [64,81], human T cell cultures [100] and
mouse differentiated Th1 cells [107,110], which will bias
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about Th1 polarization. Of note, recent studies yielded
contradictory data, showing that, under specific conditions,
MSCs may increase the levels of IFN-γ and IL-10 in the
culture supernatants [64,102], which suggests that MSCs’
influence on IFN-γ expression will depend on different fac-
tors, such as the type of stimulation, type of hematopoietic
cells present in cell culture and the presence of cytokines
in the milieu. Finally, a recently described T-bet+ Th1 cell
subpopulation co-expressing IFN-γ and IL-10 [111] was
demonstrated to be induced and expanded by MSCs [112].
These T cells arise from Th1 polarized cells that start
producing IL-10, assuming regulatory activity [112].
Likewise, TGF-β, known to be produced by MSCs, pro-
motes IL-10 production by Th1 cells which, in turn, reduces
IFN-γ expression by the same cells [113].
Thus, focusing on our experimental design, MSCs may
act directly on T cells present in MNC fraction or, poster-
iorly, on PHA-mediated Th1-polarizing cells, since MSCs’
immunomodulatory ability increases after their contact
with pro-inflammatory cytokines, whose concentration
in culture medium increases after PHA-induced MNC
activation. Namely, IFN-γ and/or TNF-α augment TGF-
β expression by MSCs [70,104], which induces IL-10
expression by Th1 cells and, consequently, reduce their
IFN-γ production. Additionally, MSCs down-regulate IFN-
γR expression on T cells surface [112], rendering them less
prone to respond to IFN-γ. Also, we should not discard
MSCs’ effect on the DC present in the cell culture that may
as well influence T cell function.
The increased mRNA expression of T-bet promoted by
MSCs, observed along all the T cell activation processes
and within each activation compartment, make us think
that MSCs are able to suppress T cell-mediated inflamma-
tory response by reducing the proportion of T cells that
undergo activation but, once initiated the activation
process, MSCs will not alter T cell differentiation’s sense
in PHA-stimulated MNC, thus, T cells will continue to
differentiate towards Th1. Nevertheless, as MSCs also
decrease IL-2 mRNA expression on T cells undergoing
activation, we may expect a limited clonal expansion of
the activated lymphocytes that will further reduce the
final number of effector T cells. Finally, there is evidence
supporting that, after the conclusion of the differenti-
ation process, MSCs are able to inhibit Th1 effector
functions. Altogether, MSCs may inhibit Th1 immune
response not by altering the sense of T cell polarization
but, instead, by reducing the number of Th1 effector cells
and by inhibiting the effector functions of differentiated
Th1 cells.
In relation to GATA-3, although some studies confirm
that MSCs modulate cytokine production by T lymphocytes
toward a Th2 pattern, there is no evidence pointing to Th2
differentiation mediated by MSCs [34,108]; accordingly,our data show no influence of MSCs on GATA-3 mRNA
expression. This finding is in agreement with the MSCs-
mediated inhibition of B cell activation and acquisition of
lymphoblast characteristics, observed in the present study.
In what concerns NK cells, PHA-induced activation is
prevented for all the three types of MSCs tested, except
for UCM-MSCs that are unable to inhibit the activation of
CD56bright NK cell subset. Once again, AT-MSCs exhibit
the most pronounced inhibitory effect.
In agreement with our results, previous studies described
the down-regulation of CD69 expression on NK cells under
the influence of BM-MSCs [114,115]. Indeed, all the effects
of MSCs already described in the literature are consistent
with the inhibition of NK cell activation: MSCs prevent NK
cell proliferation [59,95,116,117]; induce down-regulation
of functional NK receptors [59,115-119]; inhibit the expres-
sion of pro-inflammatory cytokines (such as IFN-γ and
TNF-α) [57,59,63,115-117,119] and granzyme A [119] and
prevent NK cell degranulation [119]. As a result of all the
effects aforementioned, MSCs hamper NK cell cytolytic
activity [59,116-118]. Different evidence points to an im-
portant role of PGE2, TGF-β, IDO, HLA-G5, HLA-G1 and
adenosine on NK cell inhibition, despite of some conflicting
results on this matter [57,59,63,78,79,85,86,105,115-117].
Moreover, the differences between MSCs from different
sources are still unclear, with studies yielding contradictory
data for BM-MSCs inhibitory ability [115,117,118].
According to our data, after PHA stimulation, NK cells
express perforin and TNF-α mRNA, which is down-
regulated by all three types of MSCs. This fact is in
agreement with previous studies concerning TNF-α
[63,116], but diverges from the results recently published
by DelaRosa et al. showing that perforin production
remains unchanged in the presence of either BM- and
AT-MSCs co-cultured with purified NK cells [119]. Simi-
larly, we observed that AT- and BM-MSCs induce a slight
reduction of granzyme B mRNA expression in the later
activated stage of NK cells, whereas DelaRosa et al. show
that BM- and AT-MSCs had no effect on NK cells’ gran-
zyme B expression [119]. It is worthwhile to remember
that DelaRosa’s approach differs from ours, as in our study
MSCs were co-cultured with MNC, and the presence of
other immune cells in the culture may influence NK cell
behavior. Finally, Yen et al. concluded that human embry-
onic stem cell-derived mesenchymal progenitors present a
stronger ability to inhibit NK cell function compared to
BM-MSCs, by reducing the expression of NK-activating
receptors and NK cell cytotoxic activity [118]; here, we
observe that both BM- and UCM-MSCs present a similar
ability to inhibit CD56dim NK cell activation and TNF-α
and perforin mRNA expression.
In fact, it is difficult to compare results from studies
concerning the MSCs’ immunomodulatory ability because
MSCs are highly sensitive to the microenvironment and
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tions. Their function will vary depending on the ratio
MSC:immune cells, the immune cells present in the cell
culture, the immune cell activation status and the cyto-
kines levels in the milieu [26,64,68,71,82,120], wherein
pro-inflammatory cytokines, namely IFN-γ and TNF-α,
increase MSCs’ expression of IDO [63,67,75], galectin-1
[82], PGE2 [63,67,70,104], CD200 [90], TGF-β [70,104],
IL-10 [70] and PD-L1 [110], although there are conflicting
results [121]. On the whole, this evidence point to the
improvement of the immunomodulatory ability of MSCs
whenever they are in an environment resembling a chronic
inflammation condition. Conversely, TLR3 or TLR4 stimu-
lation, mimicking an acute inflammation state, will reduce
MSCs’ immunomodulatory ability and decrease Jagged-1
and galectin-1 expression on MSCs, similarly to that ob-
served on Treg [63,66,82,84]. Thus, MSCs will adapt their
function according to the actual conditions and require-
ments of the organism.
With respect to the differences observed among the
different types of MSCs in the present study, the inhibi-
tory ability of AT-MSCs is stronger than that of BM- and
UCM-MSCs, which is in agreement with other published
studies [67,71]. Although a few studies attempted to
unravel the functional differences among AT-, BM-
and UCM-MSCs [72,121,122], recent works shed light
on this subject, showing that AT-MSCs express an
higher level of COX-1 and PGE2 [71] and UCM-MSCs
display a lower expression of PGE2 and IDO compared
to BM-MSCs [67].
Conclusion
Overall, UCM-, BM- and AT-MSCs inhibit both acquisition
of lymphoblast characteristics and activation of T cells,
wherein AT-MSCs display a more pronounced effect and
UCM-MSCs a milder effect. Of note, AT-MSCs strongly
impede T cells from proceeding from non-activated to
earlier activated stages, yielding a large proportion of T
cells that remain non-activated, whereas with UCM-MSCs,
despite the accumulation of T cells in the earlier-activated
stage, the proportion of T cells achieving the intermediate-
activated state after four days of culture is equal to that ob-
served in the absence of MSCs. Nevertheless, MSCs induce
mRNA expression of the master transcriptional regulators
of Treg and Th1 polarization on the T cells that proceed
on the activation process. Thus, MSCs may inhibit Th1
immune response not by altering the sense of T cell
polarization but, instead, by reducing the final number
of Th1 effector cells (both by preventing T cells to
undergo activation and by hampering IL-2 production by
activated T cells) and by inhibiting the effector functions
of differentiated Th1 cells.
Concerning B cells, our work showed that AT- and
BM-MSCs are capable of inhibiting their activation andacquisition of lymphoblast characteristics, whereas UCM-
MSCs are not. To the best of our knowledge, this is the
first report showing that UCM-MSC are unable to prevent
activation of B cells from MNC cultures stimulated with
PHA and display a behavior completely different from their
counterparts arising from other tissues, clearly showing
that MSCs from different tissues may imply different
immunomodulatory properties.
Finally, all three sources of MSCs tested revealed a
strong inhibitory capability over CD56dim NK cell activa-
tion, as well as over the production of TNF-α and perforin,
whereas the activation of CD56bright NK cells was only
inhibited by BM- and AT-MSCs.Abbreviations
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